Jacqueline Samantha Womersley, Gabriela Iacovou, Yumna Kathrada et al.
preprint
Interest in psychedelic treatments for mental health conditions is growing. Health care professionals will be key in the implementation, recommendation, and administration of psychedelic-assisted therapy (PAT) if and when it is approved for clinical use, making their knowledge, attitudes, and perceptions (KAPs) central to successful translation into practice. We conducted a scoping review of...
Jukka-Pekka Heikkilä
preprint
This essay supports the motion that entrepreneurship research is out of touch with the psychedelic renaissance. It defines this mismatch as selective recognition: the phenomenon encompasses personal transformation, collective practices, and market formation, while scholarly attention foregrounds particular understandings of entrepreneurial benefit. Drawing on an interdisciplinary synthesis, the...
Yuliya Knyahnytska, Reza Zomorrodi, Tyler S Kaster et al.
BACKGROUND Suicide is among the top 10 leading causes of death worldwide. Of people who died by suicide, the majority are diagnosed with depression. It is estimated that 25%-60% of people with bipolar depression (BD) will attempt suicide at least once, and 10%-15% will die by suicide. Several treatments, such as lithium, clozapine, electroconvulsive therapy, and cognitive behavioral therapy,...
Dan Petrovitch, Sean M. Mitchell, Jason van Allen et al.
preprint
Introduction: Treatment-outcome expectancies are an individual’s beliefs about how a medical or psychological intervention will affect them and others. These response expectancies represent serious potential confounds to clinical trials of psychedelic-assisted therapies for a variety of conditions because of difficulties associated with blinding psychedelic trials. On the other hand,...
Brandon G. Truax
preprint
ABSTRACT Aims To investigate real-world treatment attrition, concomitant use of pharmaceuticals with known drug-interactions, total cost of care, claims-based outcomes, and health disparities for individuals initiated on esketamine therapy in the United States. Methods Individuals aged 18-64 with >=1 adjudicated claim for esketamine intranasal spray from 2019 to 2022 in the Optum Labs Data...
Michael Alvear
preprint
Ketamine has emerged as a plausible rapid-acting treatment for post-traumatic stress disorder (PTSD), but the clinical literature is unusually easy to overstate because a small number of randomized trials are repeatedly represented across reviews, several publications reuse the same cohorts, and treatment studies are sometimes mixed with PTSD-prevention studies conducted around acute trauma....
Sophie Holland
This paper explores ketamine as a psychedelic alongside the differential impacts of psychedelic versus psycholytic effects of ketamine in a therapeutic setting. The paper examines existing research to elucidate the broad therapeutic potential of ketamine and the mechanisms underlying each modality. The primary objective is to present the differences between psychedelic and psycholytic...
Vincent Joralemon
preprint
FDA REMS and ETASU for psychedelic therapy—psilocybin, MDMA, and Spravato (esketamine)—can enhance safety yet impose clinic-only administration that limits access. Using Spravato’s REMS as precedent, this Article shows how “every-use” in-person supervision and limited distribution increase cost and strain providers even as adverse events cluster early in treatment. It proposes a...
Dimitrios Liokaftos
Microdosing consists of the regular use of sub-perceptive doses of psychedelics substances, most notably psilocybin (“magic”) mushrooms and lysergic acid diethylamide (LSD). First observed in specific environments and subcultures before spreading in wider areas of human activity, microdosing has become one of the better recognised faces of the current “psychedelics renaissance.” Building on a...
Juan Sebastián Gómez-Cañón, Carly Leininger, Danielle Mayall et al.
preprint
Abstract Music plays a central role in psilocybin therapy (PT), where playlists are designed to be supportive and stimulating over a 4–6-hour psychedelic experience. The primary design principle underlying PT music programming is that music should be affectively aligned with the onset–peak–return model of pharmacodynamic action. However, in the absence of clear acoustic criteria, this framework...